Ameritas Advisory Services LLC Has $7.28 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Ameritas Advisory Services LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 43.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,216 shares of the company’s stock after selling 6,237 shares during the period. Ameritas Advisory Services LLC’s holdings in Eli Lilly and Company were worth $7,279,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in LLY. M&G Plc bought a new position in Eli Lilly and Company in the 1st quarter valued at approximately $8,896,000. Virtu Financial LLC bought a new position in Eli Lilly and Company in the 1st quarter valued at approximately $2,138,000. China Universal Asset Management Co. Ltd. lifted its stake in Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares during the last quarter. Mutual Advisors LLC raised its stake in shares of Eli Lilly and Company by 404.8% during the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after acquiring an additional 50,197 shares during the last quarter. Finally, Chesley Taft & Associates LLC raised its stake in shares of Eli Lilly and Company by 5.4% during the second quarter. Chesley Taft & Associates LLC now owns 22,553 shares of the company’s stock valued at $20,419,000 after acquiring an additional 1,163 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Barclays reduced their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Bank of America dropped their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,008.41.

Eli Lilly and Company Trading Down 0.2 %

NYSE:LLY traded down $1.64 during midday trading on Tuesday, reaching $804.50. 252,399 shares of the stock traded hands, compared to its average volume of 3,046,964. The company has a fifty day moving average of $908.15 and a 200 day moving average of $867.39. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a market capitalization of $763.73 billion, a P/E ratio of 87.15, a PEG ratio of 3.09 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the company earned $0.10 earnings per share. The company’s quarterly revenue was up 20.4% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 13.23 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.65%. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.